Novartis Phase II iron chelator data

Novartis (NVS; SWX:NOVN) said 9-month data from 63 evaluable thalassemia patients in a Phase II trial showed than 20 mg of its ICL670 oral iron chelator gave a 26.3% reduction in liver iron concentrat...